Evidence map›Paper›PMID 38543262›Full record

ArticlePharmaceutics2024

3D Screen Printing Offers Unprecedented Anticounterfeiting Strategies for Oral Solid Dosage Forms Feasible for Large Scale Production.

Nicolle Schwarz, Marcel Enke, Franka V Gruschwitz, Daniela Winkler, Susanne Franzmann, Lisa Jescheck, Felix Hanf, Achim Schneeberger

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nicolle SchwarzLaxxon Medical GmbH, Hans-Knöll-Street 6, 07745 Jena, Germany.
Marcel EnkeLaxxon Medical GmbH, Hans-Knöll-Street 6, 07745 Jena, Germany.
Franka V GruschwitzLaxxon Medical GmbH, Hans-Knöll-Street 6, 07745 Jena, Germany.
Daniela WinklerLaxxon Medical GmbH, Hans-Knöll-Street 6, 07745 Jena, Germany.
Susanne FranzmannLaxxon Medical GmbH, Hans-Knöll-Street 6, 07745 Jena, Germany.
Lisa JescheckLaxxon Medical GmbH, Hans-Knöll-Street 6, 07745 Jena, Germany.
Felix HanfLaxxon Medical GmbH, Hans-Knöll-Street 6, 07745 Jena, Germany.
Achim SchneebergerLaxxon Medical GmbH, Hans-Knöll-Street 6, 07745 Jena, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A threat to human health in developed and, in particular, in developing countries, counterfeit medicines represent the largest identified fraud market worldwide. 3D screen printing (3DSP), an additive manufacturing technology that enables large-scale production, offers unique opportunities to combat counterfeit drugs. One such possibility is the generation of oral dosage forms with a distinct colored inner structure that becomes visible upon breakage and cannot be copied with conventional manufacturing methods. To illustrate this, we designed tablets containing a blue cross. Owing to paste properties and the limited dimensions of the cross, the production process was chosen to be continuous, involving two screen and paste changes. The two pastes (tablet body, cross) were identical except for the blue color of the latter. This ensured the build-up and mechanical stability of the resulting tablets in a mass production environment. The ensuing tablets were found to be uniform in weight and size and to comply with regulatory requirements for hardness, friability, and disintegration time (immediate release). Moreover, all tablets exhibited the covert anticounterfeit feature. The study delivers a proof-of-concept for incorporating complex structures into tablets using 3DSP and showcases the power of the technology offering new avenues for combating counterfeit drugs.

Indexed as

3D printing3D screen printingadditive manufacturinganti-counterfeitingdrug delivery systemsolid oral dosage formstablet geometry

Identifiers

PMID38543262
PMCPMC10974705
OpenAlexW4392456429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.